EP1235841A4 - Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques - Google Patents

Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Info

Publication number
EP1235841A4
EP1235841A4 EP00984183A EP00984183A EP1235841A4 EP 1235841 A4 EP1235841 A4 EP 1235841A4 EP 00984183 A EP00984183 A EP 00984183A EP 00984183 A EP00984183 A EP 00984183A EP 1235841 A4 EP1235841 A4 EP 1235841A4
Authority
EP
European Patent Office
Prior art keywords
mage2
peptide
nucleic acid
immune responses
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984183A
Other languages
German (de)
English (en)
Other versions
EP1235841A1 (fr
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Robert Chesnut
Esteban Celis
Elissa Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1235841A1 publication Critical patent/EP1235841A1/fr
Publication of EP1235841A4 publication Critical patent/EP1235841A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP00984183A 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques Withdrawn EP1235841A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45829899A 1999-12-10 1999-12-10
US458298 1999-12-10
PCT/US2000/033545 WO2001042267A1 (fr) 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Publications (2)

Publication Number Publication Date
EP1235841A1 EP1235841A1 (fr) 2002-09-04
EP1235841A4 true EP1235841A4 (fr) 2006-04-12

Family

ID=23820224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00984183A Withdrawn EP1235841A4 (fr) 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Country Status (5)

Country Link
EP (1) EP1235841A4 (fr)
JP (1) JP2003517310A (fr)
AU (1) AU2085001A (fr)
CA (1) CA2393339A1 (fr)
WO (1) WO2001042267A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
ES2533228T3 (es) * 2009-06-09 2015-04-08 Vaxon Biotech Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
JP6255360B2 (ja) * 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
MY193703A (en) * 2015-03-27 2022-10-26 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2020048990A1 (fr) * 2018-09-04 2020-03-12 Treos Bio Zrt Vaccins peptidiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022317A1 (fr) * 1994-02-16 1995-08-24 Cytel Corporation Compositions et procedes utilises pour induire une immunite par les lymphocytes t cytotoxiques
WO1997013858A2 (fr) * 1995-10-12 1997-04-17 Chiron Corporation Homologues de mage-3 du babouin, adn codant pour ceux-ci et technique d'utilisation associee
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721341A4 (fr) * 1993-08-06 1998-04-22 Cytel Corp Clonage et description des caracteristiques du gene mage-1 complet
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
WO1995022317A1 (fr) * 1994-02-16 1995-08-24 Cytel Corporation Compositions et procedes utilises pour induire une immunite par les lymphocytes t cytotoxiques
WO1997013858A2 (fr) * 1995-10-12 1997-04-17 Chiron Corporation Homologues de mage-3 du babouin, adn codant pour ceux-ci et technique d'utilisation associee
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTMAN J ET AL: "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 96, XP002135711, ISSN: 0036-8075 *
DEL GUERCIO M-F ET AL: "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 4, March 1997 (1997-03-01), pages 441 - 448, XP004094438, ISSN: 0264-410X *
See also references of WO0142267A1 *

Also Published As

Publication number Publication date
JP2003517310A (ja) 2003-05-27
CA2393339A1 (fr) 2001-06-14
EP1235841A1 (fr) 2002-09-04
WO2001042267A1 (fr) 2001-06-14
AU2085001A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
EP1225907A4 (fr) Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
EP1239866A4 (fr) Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
AU6226100A (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
IL195649A0 (en) Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same
AU7828100A (en) Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
TWI315988B (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1244465A4 (fr) Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
HUP0003761A2 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
AU2001234944A8 (en) Novel nucleic acids and polypeptides
EP1325120A4 (fr) Acides nucleiques et polypeptides
EP1341804A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1165586A4 (fr) GENE TCL-1b ET PROTEINE, PROCEDES ET COMPOSITIONS S'Y RAPPORTANT
EP1276751A4 (fr) Nouveaux acides nucleiques et polypeptides
EP1235848A4 (fr) Induction de reponses immunes cellulaires a l'antigene carcinoembryonnaire a l'aide des compositions renfermant des peptides et des acides nucleiques
EP1235841A4 (fr) Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
IL130608A0 (en) Novel nucleic and amino acid sequence
EP1237564A4 (fr) Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
EP1341803A4 (fr) Nouveaux acides nucleiques et polypeptides
IL158293A (en) Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same
EP1091752A4 (fr) Compositions contenant une proteine neutralisant l'endotoxine, derives et utilisations de ladite proteine
GB0021008D0 (en) Protein and nucleic acid sequence
IL160651A0 (en) Nucleic acid and correspondidng protein entitled 205pib5 and pharmaceutical compositions containing the same
AU2001263005A8 (en) Novel nucleic acids and polypeptides
EP1268762A4 (fr) Nouveaux acides nucleiques et polypeptides
HUP0500956A2 (en) Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOUTHWOOD, SCOTT

Inventor name: CHESNUT, ROBERT

Inventor name: CELIS, ESTEBAN

Inventor name: FIKES, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SETTE, ALESSANDRO

Inventor name: SIDNEY, JOHN

A4 Supplementary search report drawn up and despatched

Effective date: 20060227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061017